Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCADlys-PE: Catheter-directed Thrombolysis in Intermediate-High-Risk PE
NCT06487052Recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of tissue-plasminogen activator in pulmonary embolism (PE) (2 arms). Primary endpoint: Decrease in the ratio of Right Ventricle/Left Ventricle diameters at 48 hours. Started Jan 2024; status: recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT06487052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06487052.